CETP基因多态性与湖南汉族人脑梗死的相关性研究
|
摘要
目的：探讨胆固醇酯转运蛋白(CETP)基因Taq IB和-629C/A多态性与中国湖南地区汉族人群动脉粥样硬化性脑梗死的关联性,及其对血压、血脂、血糖等的影响。
方法：应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法检测238例动脉粥样硬化性脑梗死患者和162例年龄、性别相匹配的健康体检者的CETP基因Taq IB和-629C/A多态位点的基因型分布和等位基因频率,血脂中甘油三酯(TG)和总胆固醇(TC)采用氧化酶法测定；高密度脂蛋白胆固醇(HDL-C)测定先用沉淀剂沉淀,再用酶法测定上清液中的胆固醇；低密度脂蛋白胆固醇(LDL-C)由公式(LDL-C)=(TC)-(HDL-C)-(TG/5)求出；血糖(FBS)用葡萄糖氧化酶法测定。实验数据用SPSS13.0软件进行统计分析。
结果：
1.中国湖南汉族人群脑梗死组与对照组CETP基因Taq IB多态B1B1、B1B2. B2B2三种基因型频率及B1、B2等位基因频率的比较无显著性差异(P>0.05)。
2.中国湖南汉族人群脑梗死组与对照组CETP基因-629C/A多态AA, AC、CC三种基因型频率及A、C等位基因频率的比较无显著性差异(P>0.05)。
3.Taq IB脑梗死组B1B1基因型血脂、血糖、收缩压、舒张压及高血压、冠心病、糖尿病病史与B1B2+B2B2基因型比较无显著性差异(P>0.05)。
4.-629C/A脑梗死组CC基因型血脂、血糖、收缩压、舒张压及高血压、糖尿病病史与CA+AA基因型比较无显著性差异(P>0.05),CC基因型与CA+AA基因型间冠心病病史比较差异有统计学意义(P<0.05)。
5.脑梗死组各联合基因型间血脂、血糖、收缩压、舒张压及高血压、冠心病、糖尿病病史比较无显著性差异(P>0.05)。
结论：
1. CETP基因Taq IB和-629C/A多态性可能与中国湖南汉族人群的动脉粥样硬化性脑梗死发病无关。
2. CETP基因Taq IB和-629C/A多态性可能与中国湖南汉族人群的血脂、血糖、血压水平无关。
3. CETP基因Taq IB和-629C/A两位点的联合基因型可能与中国湖南汉族人群的血脂、血糖、血压水平无关。
Objective To explore the association of cholesterol ester transfer protein gene Taq IB and -629C/A polymorphism with atherosclerosis cerebral infarction (CI) in Han population in Hunan province, and the possible influence of this SNP on blood pressure, serum lipid and fasting glucose.
Methods Polymerase chain reaction-restriction fragment length polymorph (PCR-RFLP) was performed to identify the distributions of allele and genotype frequencies of SNP Taq IB and -629C/A polymorphism in cholesterol ester transfer protein gene in 238 patients with atherosclerosis CI and 162 healthy controls. Meanwhile we tested the levels of blood pressure, serum lipid, fasting glucose and BMI. All data was analyzed by SPSS 13.0.
Results
1. There is no significant difference of CETP Taq IB gene B1B1, B1B2, B2B2 genotype and B1 or B2 allelic distribution between CI patients and controls (P>0.05).
2. There is no significant difference of CETP -629C/A gene AC, AC, CC genotype and A or C allelic distribution between CI patients and controls (P>0.05).
3.The difference of blood lipids, blood sugar(FBS),blood pressure, history of hypertension, coronary heart disease, diabetes between CETP Taq IB B1B1 and B1B2+B2B2 gene type are not significant(P>0.05).
4.The difference of blood lipids, blood sugar(FBS),blood pressure, history of hypertension or diabetes between CETP -629C/A CC and CA+AA gene type are not significant(P>0.05). History of coronary heart disease in CC genotype compared CA+AA genotypes were significantly (P<0.05).
5. There are no significant differences between 4 combined gene types in lipids, glucose, blood pressure and history of hypertension, coronary heart disease, diabetes mellitus (P> 0.05).
Conclusions
1. The Taq IB and -629C/A polymorphism of CETP gene may not correlate with atherosclerosis cerebral infarction in Chinese Han population in Hunan province.
2. There is no relationship between Taq IB polymorphism of CETP gene and blood lipids, FBS or blood pressure in Chinese Han population in Hunan province. The same to -629C/A polymorphism of CETP gene.
3. There is no relationship between the polymorphism of Taq IB and -629C/A combined genotype and blood lipids, FBS or blood pressure in Chinese Han population in Hunan province.
方法：应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法检测238例动脉粥样硬化性脑梗死患者和162例年龄、性别相匹配的健康体检者的CETP基因Taq IB和-629C/A多态位点的基因型分布和等位基因频率,血脂中甘油三酯(TG)和总胆固醇(TC)采用氧化酶法测定；高密度脂蛋白胆固醇(HDL-C)测定先用沉淀剂沉淀,再用酶法测定上清液中的胆固醇；低密度脂蛋白胆固醇(LDL-C)由公式(LDL-C)=(TC)-(HDL-C)-(TG/5)求出；血糖(FBS)用葡萄糖氧化酶法测定。实验数据用SPSS13.0软件进行统计分析。
结果：
1.中国湖南汉族人群脑梗死组与对照组CETP基因Taq IB多态B1B1、B1B2. B2B2三种基因型频率及B1、B2等位基因频率的比较无显著性差异(P>0.05)。
2.中国湖南汉族人群脑梗死组与对照组CETP基因-629C/A多态AA, AC、CC三种基因型频率及A、C等位基因频率的比较无显著性差异(P>0.05)。
3.Taq IB脑梗死组B1B1基因型血脂、血糖、收缩压、舒张压及高血压、冠心病、糖尿病病史与B1B2+B2B2基因型比较无显著性差异(P>0.05)。
4.-629C/A脑梗死组CC基因型血脂、血糖、收缩压、舒张压及高血压、糖尿病病史与CA+AA基因型比较无显著性差异(P>0.05),CC基因型与CA+AA基因型间冠心病病史比较差异有统计学意义(P<0.05)。
5.脑梗死组各联合基因型间血脂、血糖、收缩压、舒张压及高血压、冠心病、糖尿病病史比较无显著性差异(P>0.05)。
结论：
1. CETP基因Taq IB和-629C/A多态性可能与中国湖南汉族人群的动脉粥样硬化性脑梗死发病无关。
2. CETP基因Taq IB和-629C/A多态性可能与中国湖南汉族人群的血脂、血糖、血压水平无关。
3. CETP基因Taq IB和-629C/A两位点的联合基因型可能与中国湖南汉族人群的血脂、血糖、血压水平无关。
Objective To explore the association of cholesterol ester transfer protein gene Taq IB and -629C/A polymorphism with atherosclerosis cerebral infarction (CI) in Han population in Hunan province, and the possible influence of this SNP on blood pressure, serum lipid and fasting glucose.
Methods Polymerase chain reaction-restriction fragment length polymorph (PCR-RFLP) was performed to identify the distributions of allele and genotype frequencies of SNP Taq IB and -629C/A polymorphism in cholesterol ester transfer protein gene in 238 patients with atherosclerosis CI and 162 healthy controls. Meanwhile we tested the levels of blood pressure, serum lipid, fasting glucose and BMI. All data was analyzed by SPSS 13.0.
Results
1. There is no significant difference of CETP Taq IB gene B1B1, B1B2, B2B2 genotype and B1 or B2 allelic distribution between CI patients and controls (P>0.05).
2. There is no significant difference of CETP -629C/A gene AC, AC, CC genotype and A or C allelic distribution between CI patients and controls (P>0.05).
3.The difference of blood lipids, blood sugar(FBS),blood pressure, history of hypertension, coronary heart disease, diabetes between CETP Taq IB B1B1 and B1B2+B2B2 gene type are not significant(P>0.05).
4.The difference of blood lipids, blood sugar(FBS),blood pressure, history of hypertension or diabetes between CETP -629C/A CC and CA+AA gene type are not significant(P>0.05). History of coronary heart disease in CC genotype compared CA+AA genotypes were significantly (P<0.05).
5. There are no significant differences between 4 combined gene types in lipids, glucose, blood pressure and history of hypertension, coronary heart disease, diabetes mellitus (P> 0.05).
Conclusions
1. The Taq IB and -629C/A polymorphism of CETP gene may not correlate with atherosclerosis cerebral infarction in Chinese Han population in Hunan province.
2. There is no relationship between Taq IB polymorphism of CETP gene and blood lipids, FBS or blood pressure in Chinese Han population in Hunan province. The same to -629C/A polymorphism of CETP gene.
3. There is no relationship between the polymorphism of Taq IB and -629C/A combined genotype and blood lipids, FBS or blood pressure in Chinese Han population in Hunan province.
引文
[1]Xu XW, Li JJ, Sheng WL, et al. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis,2008,26(1):48-62.
[2]Bersano A, Ballabio E, Bresolin N, et al. Genetic Polymorphisms for the Study of Multifactorial Stroke. Hum Mutat,2008,29(6):776-795.
[3]Mostaza JM,Martin-Jadraque R,Vicente I,et al.Patients at high risk of cerebrovascular disease:the REACH study.Cerebrovasc Dis,2009,27 (Suppl): 77-81.
[4]Romero JR, Morris J, Pikula A. Stroke prevention:modifying risk factors. Ther Adv Cardiovasc Dis,2008,2(4):287-303.
[5]Gil-Nunez AC, Vivancos-Mora J. Blood pressure as a risk factor for stroke and the impact of antihypertensive treatment. Cerebrovasc Dis,2005,20 (2):40-52.
[6]Hademenos GJ, Alberts MJ, Awad I, et al. Advances in the genetics of cerebrovascular disease and stroke. Neurology,2001,56(8):997-1008.
[7]Pick JC, Crook MA. Is type Ⅱ diabetes mellitus a disease of the innate immune system? Diabetologia,1998,41(10):1241-1248.
[8]Franeesehini G. Epidemiologie evidence for high density lipoprotein cholesterol as a risk factor for coronary artery disease[J].Am J Cardiol,2010,88:9-13.
[9]Johansan O,Abdelnoor M,Brekke M,et al.Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables[J]. Stand Cardio-vasc J,2010,35:86-91.
[10]Tall AR.Plasma cholesterol ester transfer protein. J Lipid Res,1993,34: 1255-1274.
[11]Plump AS,Masucci-Magoulus L,Bruce C.Increased atherosclerosis in apoE and LDL receptor gene knockant mice as a result of human cholesterol ester transfer protein transgene expression[J].Aterioscler Thromb Vasc Biol,1999,19(4): 1105-1110.
[12]Westerterp M, Van Der Hoogt CC, De Haan W,et al.Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in apoE×3 Leiden mice[J].Aterioscler Thromb Vasc Biol,2006,26(11):2552-2559.
[13]Zhang Z,Yamashita S,Hirano K.Expression of cholesterol ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport[J].Ateriosclerosis,2010,159(1):67-71.
[14]Van Eck M,Ye D,Hilldebrand RB.Important role for bone marrow-derived cholesterol ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice[J].Circ Res, 2010,100(5):678-685.
[15]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesterol ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[16]Erzberger P, Gombert MT, Mutschelknauss M, Wyler von Ballmoos M, BiedermannBC. A CETP polymorphism improves the diagnostic power of clinical examination in patients with cardiovascular disease. Swiss Med Wkly. 2010,140(21-22):307-13.
[17]Diamant M, Stehouwer CD, Bouter LM, Heine RJ. Elevated cholesteryl ester transfer protein concentration is associated with an increased risk for cardiovasculardisease in women, but not in men, with Type 2 diabetes:the Hoorn Study. Diabet Med,2011,24(2):117-23.
[18]Kohtaro Asayama, Hidemasa Hayashibe,et al. Increased Serum Cholesteryl Ester Transfer Protein in Obese Children. Obesity Research,2002,10,439-46.
[19]Da-Wei Chen,Jing-Fang Yang,et al. Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer's disease as a modifier for APOE ε4 in Chinese.Brain Research,2008,1187:52-57.
[20]Nir Barzilai MD,Gil Atzmon PhD,et al. Unique lipoprotein phenotype and genotype associated With Exceptional Longevity. JAMA,2003,290(15):2030-2040.
[21]Yamashita S,Hirano K,Sakai N.Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.BBA-Mol Cell Biol L,2010, 1529:257-275.
[22]Dachet C,Poirier O.Cambien F.New functional promoter polymorphism, CETP/-629 in the cetp gene related to CETP mass and HDL-C:role of Spl/Sp3 in transcriptional regulation. Aterioscler Thromb Vasc Biol,2000,20:507-515.
[23]Tai ES,Ordovas JM,Corella D,et al.The Taq IB and -629C>Apolymorphism sat the cholesterol ester transfer protein locus:a ssociations with lipid levels in a multi-ethnic population.The 1998 Singapore National Health Survey. ClinGenet, 2003,1:19-30.
[24]Parhofer KG. Beyond LDL-cholesterol:HDL-cholesterol as a target for atherosclerosis prevention.Exp Clin Endocfinol Diabetes,2005,113(8):414-417.
[25]Fumeron F,Betoulle D,Luc G,et al.Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction J Clin Invest,1995,96: 1664-1671.
[26]Thompson JF,Lira ME,Durham LK.Polymorphisms in the CETP gene and association with CETP mass and HDL levels.Atherosclerosis,2003,167:195-204.
[27]Okumura K,Matsui H,Kamiya H.Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size. Atherosclerosis,2002,161:425-431.
[28]Hsu LA,Ko YL,Hsu KH.Genetic variations in the cholesteryl ester transfer protein gene and high density lipoprotein cholesterol levels in Taiwanese Chinese.Hum Genet,2002,110:57-63.
[29]Drayna D, Jarnagin AS, McLean J, Henzel W, Koehr W, Fielding C, Lawn R.Cloning and sequencing of human cholestryl ester transfer protein cDNA. Nature,1987,327(61234):632-634.
[30]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesteryl ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[31]TCHOUA U,D'SOUZA W,MUKHAMEDOVA N,et al.The effect of cholesteryl ester transfer protein over expression and inhibition on reverse cholesterol transport[J].Cardiovasc Res,2008,77(4):732-739.
[32]HARDER C.LAU P,MENG A,et a1.Cholesteryl ester transferprotein(CETP) expression protects against diet induced atheresclerosis in SR-BI deficient mice[J]. Arteriesder Thromb Vasc Bioi,2007,27(4):858-864.
[33]MACLEAN P S,BOWER J F,VADLAMUDI S, et al. Cholesteryl ester transfer protein expression prevents diet induced atheresclerotic lesions in male db/ db mice[J]. Arterioscler Thromb Vase Biol,2003,23(8):1412-1415.
[34]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesteryl ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[35]Koizumi J,Mabuchi H,Yoshimura A,et al. Deficiency of serum cholesteryl ester transfer activity in patients with familial hyperalphalipoproteinemia. Atherosclerosis,1985,58:175.
[36]Brown ML,Inazu A,Hesler CB,et al.Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.Nature, 1989,342:448-451.
[37]Hirano K,Yamashita S,et al.Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagariarea of Japan.Arterioscler Thromb Vase Biol,1997,17:1053-1059.
[38]Dachet C,Poirier O,Cambien F,Chapman J,Rouis M..New functional promoter polymorphism,CETP/-629,in cholesteryl ester transfer protein(CETP) generelated to CETP mass and high density lipoprotein cholesterol levels:role of Spl/Sp3 inreanscriptional regulation.Arterioscler Thromb Vase Biol,2010,20(2):507-15.
[39]Kuivenhoven JA,et al.The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis[J].N Engl J Med,1998,338(2):86-93.
[40]Tenkanen H.Koskinen P,et al.Polymorphism of the gene encoding cholesteryl ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease.Hum Genet,1991,87::574-578.
[41]Area M,Montali A,et al.Lack of association of the common Taq IB polymorphism in cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis.Clin Genet,2001.60(5):374-380.
[42]Yilmaz H,Isbir T,et al.Effects of cholesterol ester transfer protein Taq IB gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients.Cell Biochem Funct,2004,23(1):23-28.
[43]Park KW,Choi JH,et al.The association of cholesteryl ester transfer protein polymorphism with high-density lipoprotein cholesterol and coronary heart disease in Koreans.Clin Genet,2003,63(1):31-38.
[44]Zheng KQ,Zhang SZ,et al.Association between cholesteryl ester transfer protein gene polymorphism and variations in lipid levels in patients with coronary heart disease.Chin Med J,2004,117(9):288-292.
[45]W JH,Lee YT,et al.Influence of CETP gene variation on plasma lipid levels and coronary heart disease:a survey in Taiwan.Atherosclerosis,2001,159(2):451-458.
[46]Klerkx AH,et al.Haplotype analysis of the cetp gene:not Taq IB,but the closely linked -629C→A polymorphism and a novel promoter variant are independently associated with CETP concertration.Hum Mol Genet,2003,12(2):111-123.
[47]Frisdal E,Klerkx A.H.,et al. Functional interaction between -629C/A,-971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Genet,2005,14:2607-2618.
[48]Amaki T,Suzuki T,Nakamura F,et al.Circulming malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease.Heart,2004,90(10): 1211-1213.
[49]Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease：assessing the data from Framingham to the Veterans Affaim High-density Lipoprotein Intervention Trial[J]. Am J Cardiol, 2000,86(12A):19L-22L.
[50]Boekholdt SM,Kuivenhoven JA,et al.CETP gene variation:relation to lipid parameters and cardiovascular[J]. Current Opin Lipidol,2004,15(4):393-398.
[51]Clark RW,Sutifn TA,et al.Raising high density lipoprotein in human through inhibition of cholesterol ester transfer protein:an initial multidose study of torcetrapib[J].Arterioscler Thromb Vas Biol,2004.，24(3):490-497.
[52]Klerkx AH,et al.CETP concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary heart disease.Eur J Clin Invest,2004,34(1):21-28.
[53]Boekholdt SM,et al.Cholesterol ester transfer protein Taq IB variant,high density lipoprotein cholesterol levels,cardiovascular risk,and efficiency of pravastatin treatment:individual patient meta-analysis of 13,677 subjects. Circulation,2005, 11(3):278-287.
[54]Lu H,et al.Haplotype analysis of cholesterol ester transfer protein gene promoter:a clue to an unsolved mystery of Taq IB polymorphism.J Mol Med,2003,81:246-255.
[55]Borggreve S.E,Hillege H.L, Wolffen Buttel B.H,et al.An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol:a population based study. J Clin Endocrinol. Metab,2006,91:3382-3388.
[56]Tsai MY,Johnson C,Linda Kao,et al.Cholesteryl ester transfer protein genetic polymorphisms,HDL cholesterol,and subclinical cardiovascular disease in the Multi Ethnic Study of Atherosclerosis. Atherosclerosis,2008,200:359-367.
[1]Yusuf S, Reddy S, Ounpuu S, Anand S.Global burden of cardiovascular diseases: part I:general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation,2001,104:2746-2753
[2]Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 1. (Adult Treatment Panel Ⅲ) final report. Circulation,2002, 106:3143-3421
[3]Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation,2004,110:227-239[Erratum, Circulation 2004;110:763].
[4]LaRosa JC, He J, Vupputuri S.Effect of statins on risk of coronary disease:a meta-analysis of randomized controlled trials. J Am Med Assoc,1999,282: 2340-2346.
[5]Zilversmit DB, Hughes LB, Balmer J. Stimulation of cholesterol ester exchange by lipoprotein-free rabbit plasma. Biochim Biophys Acta,1975,409:393-398.
[6]Chajek T, Fielding CJ. Isolation and characterization of a human serum cholesteryl ester transfer protein. Proc Natl Acad Sci USA,1978,75:3445-3449.
[7]Deckelbaum RJ, Eisenberg S, Oschry Y, Butbul E, Sharon I, Olivecrona T.Reversible modification of human plasma low density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J Biol Chem,1982,257:6509-6517.
[8]Swenson TL, Brocia RW, Tall AR.Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J Biol Chem,1988,263: 5150-5157.
[9]Glomset JA.The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res,1968,9:155-167.
[10]Miller NE, Thelle DS, Forde OH, Mjos OD.The Troms heart-study. High-density lipoprotein and coronary heart disease:a prospective case-control study. Lancet,1977,1(8019):965-968.
[11]Gordon DJ, Rifkind BM.High-density lipoprotein:the clinical implication of recent studies. N Engl J Med,1989,321:1311-1316.
[12]Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP, PREVEND Study Group.An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab,2006,91:3382-3388.
[13]Linsel-Nitschke P, Tall AR.HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov,2005,4:193-205.(Erratum in:Nat Rev Drug Discov.2005 Aug;4(8):648).
[14]Sikorski JA.Oral cholesteryl ester transfer protein (CETP) inhibitors:a potential new approach for treating coronary artery disease. J Med Chem,2006,49(1): 1-22.
[15]Parini P, Rudel LL. Is there a need for cholesteryl ester transfer protein inhibition? Arterioscler Thromb Vasc Biol,2003,23:374-375.
[16]Watts GF.The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Clin Sci,2002,103:595-597.
[17]Joy T, Hegele RA.The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol,2009,24:364-371.
[18]Neeli H, Rader DJ.Cholesteryl ester transfer protein(CETP) inhibitors:is there life after torcetrapib? Cardiol Clin,2008,26(4):537-546.
[19]Rennings AJM, Stalenhoef AFH JTT-705:is there still future for a CETP inhibitor after torcetrapib? Expert Opin Investig Drugs,2008,17(10):1589-1597.
[20]Brown BG, Zhao XQ. Nicotinic acid alone or in combinations for reduction of cardiovascular risk. Am J Cardiol,2008,101:58B-62B.
[21]Hunt JA, Lu Z.Cholesteryl ester transfer protein (CETP)inhibitors. Curr Topics Med Chem,2009,9:419-427.
[22]Tall AR, Yvan-Charvet L, Wang N.The failure of torcetrapib:was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol,2007,27:257-260.
[23]Tall AR.CETP inhibitors to increase HDL cholesterol levels. N Engl J Med,2007,356:1364-1366.
[24]Gotto AM. Does torcetrapib reduce the progression of atherosclerotic disease? Nat Clin Pract Cardiovasc Med,2007,4:478-479.
[25]Toth PP.Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Curr Atheroscler Rep,2007,9(1):81-88.
[26]Howes LG, Kostner K.The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs,2007,16:1509-1516.
[27]Potter LK, Sprecher DL, Walker MC, Tobin FL. Mechanism of inhibition defines CETP activity:a mathematical model for CETP in vitro. J Lipid Res,2009,50(11):2222-2234.
[28]Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR.Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol,2003,23:160-167.
[29]Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW.Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature,1993,364:73-75.
[30]Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M,Okamoto H, Kamada M, Mizushima A.Effect of antisense oligonucleotides against cholesteryl ester transfer protein Cholesteryl ester transfer protein inhibition on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem,1998,273:5033-5036.
[31]Okamoto H, Yonemori F, Waktiani K, Minowa T, Maeda K, Shinkai H.A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature,2000,406:203-207.
[32]Huang Z, Inazu A, Nohara A, Hagashita T, Mabuchi H.Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci,2002,103:587-594.
[33]Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B for the ILLUMINATE Investigators.Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med,2007,357:2109-2122.
[34]Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, for the ILLUSTRATE Investigators.Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med,2007,356:1304-1316.
[35]Kastelein JJP, Van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; for the RADIANCE 1 Investigators.Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med,2007,356:1620-1630.
[36]Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, for the RADIANCE 2 Investigators.Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study):a randomised, double-blind trial. Lancet,2007,370:153-160.
[37]Rano TA, Sieber-McMaster E, Pelton PD, Yang M, Demarest KT, Kuo GH.Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4tetrahydroquinoline platform. Bioorg Med Chem Lett,2009,19:2456-2460.
[38]Kuo GH, Rano T, Pelton P, Demarest KT, Gibbs AC, Murray WV, Damiano BP, Connelly MA. Design, synthesis, and biological evaluation of (2R, alphaS)-3,4-dihydro-2-[3-(1,1,2,2tetrafluoroethoxy)phenyl]-5-[3-(trifluorometho xy)-phenyl]alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. J Med Chem,2009, 52:1768-1772.
[39]Bruce C, Beamer LJ, Tall AR.The implications of the structure of the bactericidal/permeability increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol,1998,8:426-434.
[40]Kawano K, Qin SC, Lin M, Tall AR, Jiang XC.Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo. J Biol Chem,2000,275:29477-29481.
[41]Tall AR.Plasma cholesteryl ester transfer protein. J Lipid Res,1993,34:1255-1274.
[42]Drayna D, Jarnagin AS, McLean J, Henzel W, Koehr W, Fielding C, Lawn R.Cloning and sequencing of human cholestryl ester transfer protein cDNA. Nature,1987,327(61234):632-634.
[43]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesteryl ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[44]Dullaart RPF, Sluiter WJ.Common variation in the CETP gene and the implications for cardiovascular disease and its treatment:an updated analysis. Pharmacogenomics,2008,9(6):747-763.
[45]Qiu X, Mistry A, Ammirati MJ, Chrunyk BA, Clark RW, Cong Y, Culp JS, Danley DE, Freeman TB, Geoghegan KF, Griffor MC, Hawrylik SJ, Hayward CM, Hensley P, Hoth LR, Karam GA, Lira ME, Lloyd DB, McGrath KM, Stutzman-Engwall KJ, Subashi AK, Subashi TA, Thompson JF, Wang IK, Zhao H, Seddon AP.Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol,2007,14:106-113.
[46]Jiang XC, Bruce C, Cocke T, Wang S, Boguski M, Tall AR.Point mutagenesis of positively charged amino acids of cholesteryl ester transfer protein:conserved residues within the lipid transfer/lipopolysaccharide binding protein gene family essential for function. Biochemistry,1995,34(21):7258-7263.
[47]Pape ME, Ulrich RG, Rea TJ, Marotti KR, Melchior GW.Evidence that the nonparenchymal cells of the liver are the principal source of cholesteryl ester transfer protein in primates. J Biol Chem,1991,266(20):12829-12831.
[48]Martin LJ, Connelly PW, Nancoo D, Wood N, Zhang ZJ, Maguire G, Quinet E, Tall AR, Marcel YL, McPherson R.Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in man:relationship to apoprotein E genotype. J Lipid Res,1993,34:437-446.
[49]Radeau T, Lau P, Robb M, McDonnell M, Ailhaud G, McPherson R.Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J Lipid Res,1995,36:2552-2561.
[50]Tall AR (1993) Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274
[51]Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR.Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol,2003,23:160-167.
[52]Benoist F, Lau P, McDonnell M, Doelle H, Milne R, McPherson R.Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue. J Biol Chem,1997,272(38): 23572-23577.
[53]Gue'rin M, Dolphin PJ, Chapman MJ.Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb,1994,14:679-685.
[54]Bruce C, Davidson WS, Kussie P, Lund-Katz S, Phillips MC, Ghosh R, Tall AR.Molecular determinants of plasma cholesteryl ester transfer protein binding to high density lipoprotein.J Biol Chem,1995,270(19):11532-11542.
[55]Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis,1984,4:225-231.
[56]Hamilton JA, Deckelbaum RJ. Crystal structure of CETP:new hopes for raising HDL to decrease risk of cardiovascular disease? Nat Struct Mol Biol.2007,14: 95-97.
[57]Kontush A, Capman MJ.Functionally defective HDL:a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev,2006.3:342-374.
[58]Kontush A, Guerin M, Chapman MJ,Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med,2008,5(6): 329-336.
[59]Glomset JA.The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res,1968,9:155-167.
[60]Ross R, Glomset JA.Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science,1973,180:1332-1339.
[61]Badimon JJ, Badimon L, Fuster V.Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest, 1990,85:1234-1241.
[62]Moreno PR, Sanz J, Fuster V.Promoting mechanisms of vascular health. J Am Coll Cardiol,2009,53(25):2315-2325.
[63]Yancey PG, Bortnick AE, Kellner-Weibel G, de-la Llera-Moya M, Phillips MC, Rothblat GH.Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol,2003,23:712-719.
[64]Takahashi Y, Smith JD.Cholesterol efflux to apolipoprotein Al involves endocytosis and re-secretion in a calcium-dependent pathway. Proc Natl Acad Sci USA,1999,96:11358-11363.
[65]Williams DL, Connelly MA, Temel RE, Swarnakar S, Phillips MC, de la Llera-Moya M, Rothblat GH.Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol,1999,10:329-339.
[66]Brewer HB Jr.High-density lipoproteins:a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol, 2004,24(3):387-391.
[67]Schwartz CC, Vlahcevic ZR. Berman M, Meadows JG, Nisman RM, Swell L.Central role of high density lipoprotein in plasma free cholesterol metabolism. J Clin Invest,1982,70(1):105-116.
[68]Schwartz CC, Vlahcevic ZR, Halloran LG, Swell L.An in vivo evaluation in man of the transfer of esterified cholesterol between lipoproteins and into the liver and bile. Biochim Biophys Acta,1981,663(1):143-162.
[69]Schwartz CC, Berman M, Vlahcevic ZR, Halloran LG, Gregory DH, Swell L.Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites. J Clin Invest,1978,61(2):408-423.
[70]Lewis GF, Rader DJ.New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res,2005,96:1221-1232.
[71]Petoumenos V, Nickenig G, Werner N.High density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med,2008,13(11): 4623-4635.
[72]Barter PJ, Baker PW, Rye KA.Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol, 2002,13:285-288.
[73]Kontush A, Chapman MJ.Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med,2006,3:342-374.
[74]Atzmon G, Rincon M, Rabizadeh P, Barzilai N.Biological evidence for inheritance of exceptional longevity. Mech Ageing Dev,2005,126:341-345.
[75]Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL,Lipton R, Cheng S, Shuldiner AR.Unique lipoprotein phenotype and genotype associated with exceptional longevity. J Am Med Assoc,2003,290:2030-2040.
[76]Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR.A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res,2004,45:948-953.
[77]Franceschini G, Sirtori M, Gianfranceschi G Sirtori CR.Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality. Metab Clin Exp,1981,30(5):502-509.
[78]Franceschini G, Calabresi L.Normal vascular function despite low levelsof high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I-Milano mutant. Circulation,2007,116:2165-2172.
[79]Franceschini G, Calabresi L, Chiesa G, Parolini C, Sirtori CR,Canavesi M, Bernini F.Increased cholesterol efflux potential of sera from apoAI Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol,1999,19:1257-1262.
[80]Calabresi L, Canavesi M, Bernini F, Franceschini GCell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry,1999,38:16307-16314
[81]Bielicki JK, Oda MN.Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry,2010,41:2089-2096.
[82]Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK.Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol,2006,48:1459-1468.
[83]Parolini C, Chiesa G, Gong E, Caligari S, Cortese MM, Koga T, Forte TM, Rubin EM.Apolipoprotein A-I and the molecular variant apoAIMilano: evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis,2005,183:222-229.
[84]Lebherz C, Sanmiguel J, Wilson J, Rader D.Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol,2007,6:15.
[85]Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ,Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R.Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial. JAMA,2003,290:2292-2300.
[86]Nicholls SJ, Tuzcu EM, Crowe T, Sipahi I, Schoenhagen P,Kapadia S, Hazen SL, Wun CC, Norton M, Ntanios F, Nissen SE.Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol,2006,47:1967-1975.
[87]Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M, Rothblat GH, Phillips MC, Rader DJ.Macrophage reverse cholesterol transport in mice expressing apoA-1 Milano. Arterioscler Thromb Vasc Biol.2009,29: 1496-1501.
[88]Inazu A, Quinet EM, Wang S, Brown ML, Stevenson S, Barr ML, Moulin P, Tall AR.Alternative splicing of the mRNA encoding human cholesteryl ester transfer protein. Biochemistry,1992,31:2352-2358.
[89]Quinet E, Yang TP, Marinos C, Tall A.Inhibition of the cellular secretion of cholesteryl ester transfer protein by a variant protein formed by alternative splicing of mRNA. J Biol Chem,1993,268:16891-16894.
[90]Yamashita S, Hirano KI, Sakai N, Matsuzawa Y.Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta,2010,1529:257-275.
[91]Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y.Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omaguri area of Japan. Arterioscler Thromb Vasc Biol,1997,17:1053-1059.
[92]Nagano M, Yamashita S, Hirano K, Takano M, Maruyama T, Ishihara M, Sagehashi Y, Kujiraoka T, Tanaka K, Hattori H, Sakai N, Nakajima N, Egashira T, Matsuzawa Y.Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb,2004,11(3):110-121.
[93]Rhyne J, Ryan MJ, White C, Chimonas T, Miller M.The two novel CETP mutations GIn87X and GIn165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med,2006,84:647-650.
[94]Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Tall AR.Increased coronary heart disease in Japanese American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest,1996, 97:2917-2923.
[95]MacLean PS, Vadlamudi S, Mac Donald KG, Pories WJ, Barakat HA. Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus. J Clin Endocrinol Metabol,2005,90:2250-2258.
[96]Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ.Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol,2005,16:139-145.
[97]Boekholdt SM, Thomson JF.Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res,2005,44:1080-1093.
[98]Thompson A, DiAngelantonio E, Sarwar N, Erqou S, Salcheen D, Dillaart RPF, Keavney B, Ye Z, Danesh J.Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA,2008,299(23):2777-2788.
[99]Sirtori CR, Mombelli G.Viability of developing CETP inhibitors. Cardiovasc Ther,2008,26:135-146.
[100]Agellon LB, Walsh A, Ayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem,1991,266:10796-10801.
[101]Jiang XC, Masucci-Magoulas L, Mar J, Lin M, Walsh A, reslow JL, Tall A.Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein: mechanism to explain accumulation of lipoprotein B particles. J Biol Chem,1993,268:27406-27412.
[102]Haraki T, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H.Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis,1997,132:229-236.
[103]Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJG, Jukema JW, Luben R, Bingham SA, Day NE, Kastelein JJP, Khaw KT.Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women:the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study. Circulation,2004,110:1418-1423.
[104]De Grooth GJ, Smilde TJ, van Wissen S, Klerkx AHEM, Zwinderman AH, Fruchart JC, Kastelein JJP, Stalenhoef AFH, Kuivenhoven JA.The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis,2004,173:261-267.
[105]Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U.The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis,2010,169:113-120.
[106]Thomas LJ, Hammond RA, Forsberg EM, Geoghegan-Barek KM, Karalius BH, Marsh HC Jr, Ritterhaus CW.Coadministration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum Vaccin,2011,5(2):79-84.
[107]Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ.Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res,2006,47:537-552.
[108]Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED,Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ.Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein:an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol,2004,24:490-497.
[109]Davidson MH, McKenney JM, Shear CL, Revkin JH.Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol,2006,48:1774-1781.
[110]Mc Kenney JM, Davidson MH, Shear CL, Revkin JH.Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol,2006,48:1782-1790.
[111]Hu X, Dietz JD, Xia C, Loging Knight DR, WT Smith AH, Yuan H, Perry DA, Keiser J.Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology,2009,50(5):2211-2219.
[112]Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M 3rd, West SH, White V, Woltmann RF.Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol,2008,154:1465-1473.
[113]Schmeck C, Gielen-Haertwig H, Vakalopoulos A, Bischoff H, Li V, Wirtz Q Weber O.Novel tetrahydrochinoline derived CETP inhibitors. Bioorg Med Chem Lett,2010,20(5):1740-1743.
[114]Boettcher M, Heinig R, Schafer A, Wensing GSafety, tolerability, pharmacodynamics and pharmacokinetics of BAY 60-5521—a new CETP inhibitor. 0th World Conf Clin Pharmacol Ther (July 27-August 1, Quebec), 2008, Abstract T2H023.
[115]Maeda K,et al.S-(2-(acylamino)phenyl)2,2- dimethylpropanethioates as CETP inhibitors. Bioorg Med Chem Lett,2004,14(10):2589-2591.
[116]Shinkai H, Maeda K, Yamasaki T, Okamoto H, Uchida I.Bis(2-(Acylamino) phenyl) disulfides,2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J Med Chem,2000,43(19):3566-3572.
[117]De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J,Zwinderman AH, Posma JL, van Tol A, Kastelein JJ.Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans:a randomized phase Ⅱ dose-response study. Circulation,2010,105(18):2159-2165.
[118]Stein EA, Stroes ESG, Steiner G, Buckley BM DPhild, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJP.Safety and Tolerability of dalcetrapib. Am J Cardiol,2009,104:82-91.
[119]Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J,Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA.Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet 2007,370(9603):1907-1914.
[120]Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM,Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC.Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J,2009,157(2):352-360.
[121]Cunningham D, Lin W, Hoth LR, Danley DE, Ruggeri RB, Geoghegan KF, Chrunyk BA, Boyd JG.Biophysical and biochemical approach to locating an inhibitor binding site on cholestreyl ester transfer protein. Bioconjug Chem,2008,19:1604-1613.
[122]Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H.A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature,2009,406:203-207.
[123]Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ.Description of the torcetrabip series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res,2010,47:537-552.
[124]Cannon CP, Dansky HM, Davidson M, Gotto AM Jr., Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P, DEFINE investigators Design of the DEFINE trial. Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J,2009,158(4):513-519.
[2]Bersano A, Ballabio E, Bresolin N, et al. Genetic Polymorphisms for the Study of Multifactorial Stroke. Hum Mutat,2008,29(6):776-795.
[3]Mostaza JM,Martin-Jadraque R,Vicente I,et al.Patients at high risk of cerebrovascular disease:the REACH study.Cerebrovasc Dis,2009,27 (Suppl): 77-81.
[4]Romero JR, Morris J, Pikula A. Stroke prevention:modifying risk factors. Ther Adv Cardiovasc Dis,2008,2(4):287-303.
[5]Gil-Nunez AC, Vivancos-Mora J. Blood pressure as a risk factor for stroke and the impact of antihypertensive treatment. Cerebrovasc Dis,2005,20 (2):40-52.
[6]Hademenos GJ, Alberts MJ, Awad I, et al. Advances in the genetics of cerebrovascular disease and stroke. Neurology,2001,56(8):997-1008.
[7]Pick JC, Crook MA. Is type Ⅱ diabetes mellitus a disease of the innate immune system? Diabetologia,1998,41(10):1241-1248.
[8]Franeesehini G. Epidemiologie evidence for high density lipoprotein cholesterol as a risk factor for coronary artery disease[J].Am J Cardiol,2010,88:9-13.
[9]Johansan O,Abdelnoor M,Brekke M,et al.Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables[J]. Stand Cardio-vasc J,2010,35:86-91.
[10]Tall AR.Plasma cholesterol ester transfer protein. J Lipid Res,1993,34: 1255-1274.
[11]Plump AS,Masucci-Magoulus L,Bruce C.Increased atherosclerosis in apoE and LDL receptor gene knockant mice as a result of human cholesterol ester transfer protein transgene expression[J].Aterioscler Thromb Vasc Biol,1999,19(4): 1105-1110.
[12]Westerterp M, Van Der Hoogt CC, De Haan W,et al.Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in apoE×3 Leiden mice[J].Aterioscler Thromb Vasc Biol,2006,26(11):2552-2559.
[13]Zhang Z,Yamashita S,Hirano K.Expression of cholesterol ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport[J].Ateriosclerosis,2010,159(1):67-71.
[14]Van Eck M,Ye D,Hilldebrand RB.Important role for bone marrow-derived cholesterol ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice[J].Circ Res, 2010,100(5):678-685.
[15]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesterol ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[16]Erzberger P, Gombert MT, Mutschelknauss M, Wyler von Ballmoos M, BiedermannBC. A CETP polymorphism improves the diagnostic power of clinical examination in patients with cardiovascular disease. Swiss Med Wkly. 2010,140(21-22):307-13.
[17]Diamant M, Stehouwer CD, Bouter LM, Heine RJ. Elevated cholesteryl ester transfer protein concentration is associated with an increased risk for cardiovasculardisease in women, but not in men, with Type 2 diabetes:the Hoorn Study. Diabet Med,2011,24(2):117-23.
[18]Kohtaro Asayama, Hidemasa Hayashibe,et al. Increased Serum Cholesteryl Ester Transfer Protein in Obese Children. Obesity Research,2002,10,439-46.
[19]Da-Wei Chen,Jing-Fang Yang,et al. Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer's disease as a modifier for APOE ε4 in Chinese.Brain Research,2008,1187:52-57.
[20]Nir Barzilai MD,Gil Atzmon PhD,et al. Unique lipoprotein phenotype and genotype associated With Exceptional Longevity. JAMA,2003,290(15):2030-2040.
[21]Yamashita S,Hirano K,Sakai N.Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.BBA-Mol Cell Biol L,2010, 1529:257-275.
[22]Dachet C,Poirier O.Cambien F.New functional promoter polymorphism, CETP/-629 in the cetp gene related to CETP mass and HDL-C:role of Spl/Sp3 in transcriptional regulation. Aterioscler Thromb Vasc Biol,2000,20:507-515.
[23]Tai ES,Ordovas JM,Corella D,et al.The Taq IB and -629C>Apolymorphism sat the cholesterol ester transfer protein locus:a ssociations with lipid levels in a multi-ethnic population.The 1998 Singapore National Health Survey. ClinGenet, 2003,1:19-30.
[24]Parhofer KG. Beyond LDL-cholesterol:HDL-cholesterol as a target for atherosclerosis prevention.Exp Clin Endocfinol Diabetes,2005,113(8):414-417.
[25]Fumeron F,Betoulle D,Luc G,et al.Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction J Clin Invest,1995,96: 1664-1671.
[26]Thompson JF,Lira ME,Durham LK.Polymorphisms in the CETP gene and association with CETP mass and HDL levels.Atherosclerosis,2003,167:195-204.
[27]Okumura K,Matsui H,Kamiya H.Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size. Atherosclerosis,2002,161:425-431.
[28]Hsu LA,Ko YL,Hsu KH.Genetic variations in the cholesteryl ester transfer protein gene and high density lipoprotein cholesterol levels in Taiwanese Chinese.Hum Genet,2002,110:57-63.
[29]Drayna D, Jarnagin AS, McLean J, Henzel W, Koehr W, Fielding C, Lawn R.Cloning and sequencing of human cholestryl ester transfer protein cDNA. Nature,1987,327(61234):632-634.
[30]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesteryl ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[31]TCHOUA U,D'SOUZA W,MUKHAMEDOVA N,et al.The effect of cholesteryl ester transfer protein over expression and inhibition on reverse cholesterol transport[J].Cardiovasc Res,2008,77(4):732-739.
[32]HARDER C.LAU P,MENG A,et a1.Cholesteryl ester transferprotein(CETP) expression protects against diet induced atheresclerosis in SR-BI deficient mice[J]. Arteriesder Thromb Vasc Bioi,2007,27(4):858-864.
[33]MACLEAN P S,BOWER J F,VADLAMUDI S, et al. Cholesteryl ester transfer protein expression prevents diet induced atheresclerotic lesions in male db/ db mice[J]. Arterioscler Thromb Vase Biol,2003,23(8):1412-1415.
[34]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesteryl ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[35]Koizumi J,Mabuchi H,Yoshimura A,et al. Deficiency of serum cholesteryl ester transfer activity in patients with familial hyperalphalipoproteinemia. Atherosclerosis,1985,58:175.
[36]Brown ML,Inazu A,Hesler CB,et al.Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.Nature, 1989,342:448-451.
[37]Hirano K,Yamashita S,et al.Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagariarea of Japan.Arterioscler Thromb Vase Biol,1997,17:1053-1059.
[38]Dachet C,Poirier O,Cambien F,Chapman J,Rouis M..New functional promoter polymorphism,CETP/-629,in cholesteryl ester transfer protein(CETP) generelated to CETP mass and high density lipoprotein cholesterol levels:role of Spl/Sp3 inreanscriptional regulation.Arterioscler Thromb Vase Biol,2010,20(2):507-15.
[39]Kuivenhoven JA,et al.The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis[J].N Engl J Med,1998,338(2):86-93.
[40]Tenkanen H.Koskinen P,et al.Polymorphism of the gene encoding cholesteryl ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease.Hum Genet,1991,87::574-578.
[41]Area M,Montali A,et al.Lack of association of the common Taq IB polymorphism in cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis.Clin Genet,2001.60(5):374-380.
[42]Yilmaz H,Isbir T,et al.Effects of cholesterol ester transfer protein Taq IB gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients.Cell Biochem Funct,2004,23(1):23-28.
[43]Park KW,Choi JH,et al.The association of cholesteryl ester transfer protein polymorphism with high-density lipoprotein cholesterol and coronary heart disease in Koreans.Clin Genet,2003,63(1):31-38.
[44]Zheng KQ,Zhang SZ,et al.Association between cholesteryl ester transfer protein gene polymorphism and variations in lipid levels in patients with coronary heart disease.Chin Med J,2004,117(9):288-292.
[45]W JH,Lee YT,et al.Influence of CETP gene variation on plasma lipid levels and coronary heart disease:a survey in Taiwan.Atherosclerosis,2001,159(2):451-458.
[46]Klerkx AH,et al.Haplotype analysis of the cetp gene:not Taq IB,but the closely linked -629C→A polymorphism and a novel promoter variant are independently associated with CETP concertration.Hum Mol Genet,2003,12(2):111-123.
[47]Frisdal E,Klerkx A.H.,et al. Functional interaction between -629C/A,-971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Genet,2005,14:2607-2618.
[48]Amaki T,Suzuki T,Nakamura F,et al.Circulming malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease.Heart,2004,90(10): 1211-1213.
[49]Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease：assessing the data from Framingham to the Veterans Affaim High-density Lipoprotein Intervention Trial[J]. Am J Cardiol, 2000,86(12A):19L-22L.
[50]Boekholdt SM,Kuivenhoven JA,et al.CETP gene variation:relation to lipid parameters and cardiovascular[J]. Current Opin Lipidol,2004,15(4):393-398.
[51]Clark RW,Sutifn TA,et al.Raising high density lipoprotein in human through inhibition of cholesterol ester transfer protein:an initial multidose study of torcetrapib[J].Arterioscler Thromb Vas Biol,2004.，24(3):490-497.
[52]Klerkx AH,et al.CETP concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary heart disease.Eur J Clin Invest,2004,34(1):21-28.
[53]Boekholdt SM,et al.Cholesterol ester transfer protein Taq IB variant,high density lipoprotein cholesterol levels,cardiovascular risk,and efficiency of pravastatin treatment:individual patient meta-analysis of 13,677 subjects. Circulation,2005, 11(3):278-287.
[54]Lu H,et al.Haplotype analysis of cholesterol ester transfer protein gene promoter:a clue to an unsolved mystery of Taq IB polymorphism.J Mol Med,2003,81:246-255.
[55]Borggreve S.E,Hillege H.L, Wolffen Buttel B.H,et al.An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol:a population based study. J Clin Endocrinol. Metab,2006,91:3382-3388.
[56]Tsai MY,Johnson C,Linda Kao,et al.Cholesteryl ester transfer protein genetic polymorphisms,HDL cholesterol,and subclinical cardiovascular disease in the Multi Ethnic Study of Atherosclerosis. Atherosclerosis,2008,200:359-367.
[1]Yusuf S, Reddy S, Ounpuu S, Anand S.Global burden of cardiovascular diseases: part I:general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation,2001,104:2746-2753
[2]Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 1. (Adult Treatment Panel Ⅲ) final report. Circulation,2002, 106:3143-3421
[3]Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation,2004,110:227-239[Erratum, Circulation 2004;110:763].
[4]LaRosa JC, He J, Vupputuri S.Effect of statins on risk of coronary disease:a meta-analysis of randomized controlled trials. J Am Med Assoc,1999,282: 2340-2346.
[5]Zilversmit DB, Hughes LB, Balmer J. Stimulation of cholesterol ester exchange by lipoprotein-free rabbit plasma. Biochim Biophys Acta,1975,409:393-398.
[6]Chajek T, Fielding CJ. Isolation and characterization of a human serum cholesteryl ester transfer protein. Proc Natl Acad Sci USA,1978,75:3445-3449.
[7]Deckelbaum RJ, Eisenberg S, Oschry Y, Butbul E, Sharon I, Olivecrona T.Reversible modification of human plasma low density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J Biol Chem,1982,257:6509-6517.
[8]Swenson TL, Brocia RW, Tall AR.Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J Biol Chem,1988,263: 5150-5157.
[9]Glomset JA.The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res,1968,9:155-167.
[10]Miller NE, Thelle DS, Forde OH, Mjos OD.The Troms heart-study. High-density lipoprotein and coronary heart disease:a prospective case-control study. Lancet,1977,1(8019):965-968.
[11]Gordon DJ, Rifkind BM.High-density lipoprotein:the clinical implication of recent studies. N Engl J Med,1989,321:1311-1316.
[12]Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP, PREVEND Study Group.An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab,2006,91:3382-3388.
[13]Linsel-Nitschke P, Tall AR.HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov,2005,4:193-205.(Erratum in:Nat Rev Drug Discov.2005 Aug;4(8):648).
[14]Sikorski JA.Oral cholesteryl ester transfer protein (CETP) inhibitors:a potential new approach for treating coronary artery disease. J Med Chem,2006,49(1): 1-22.
[15]Parini P, Rudel LL. Is there a need for cholesteryl ester transfer protein inhibition? Arterioscler Thromb Vasc Biol,2003,23:374-375.
[16]Watts GF.The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Clin Sci,2002,103:595-597.
[17]Joy T, Hegele RA.The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol,2009,24:364-371.
[18]Neeli H, Rader DJ.Cholesteryl ester transfer protein(CETP) inhibitors:is there life after torcetrapib? Cardiol Clin,2008,26(4):537-546.
[19]Rennings AJM, Stalenhoef AFH JTT-705:is there still future for a CETP inhibitor after torcetrapib? Expert Opin Investig Drugs,2008,17(10):1589-1597.
[20]Brown BG, Zhao XQ. Nicotinic acid alone or in combinations for reduction of cardiovascular risk. Am J Cardiol,2008,101:58B-62B.
[21]Hunt JA, Lu Z.Cholesteryl ester transfer protein (CETP)inhibitors. Curr Topics Med Chem,2009,9:419-427.
[22]Tall AR, Yvan-Charvet L, Wang N.The failure of torcetrapib:was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol,2007,27:257-260.
[23]Tall AR.CETP inhibitors to increase HDL cholesterol levels. N Engl J Med,2007,356:1364-1366.
[24]Gotto AM. Does torcetrapib reduce the progression of atherosclerotic disease? Nat Clin Pract Cardiovasc Med,2007,4:478-479.
[25]Toth PP.Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Curr Atheroscler Rep,2007,9(1):81-88.
[26]Howes LG, Kostner K.The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs,2007,16:1509-1516.
[27]Potter LK, Sprecher DL, Walker MC, Tobin FL. Mechanism of inhibition defines CETP activity:a mathematical model for CETP in vitro. J Lipid Res,2009,50(11):2222-2234.
[28]Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR.Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol,2003,23:160-167.
[29]Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW.Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature,1993,364:73-75.
[30]Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M,Okamoto H, Kamada M, Mizushima A.Effect of antisense oligonucleotides against cholesteryl ester transfer protein Cholesteryl ester transfer protein inhibition on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem,1998,273:5033-5036.
[31]Okamoto H, Yonemori F, Waktiani K, Minowa T, Maeda K, Shinkai H.A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature,2000,406:203-207.
[32]Huang Z, Inazu A, Nohara A, Hagashita T, Mabuchi H.Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci,2002,103:587-594.
[33]Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B for the ILLUMINATE Investigators.Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med,2007,357:2109-2122.
[34]Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, for the ILLUSTRATE Investigators.Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med,2007,356:1304-1316.
[35]Kastelein JJP, Van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; for the RADIANCE 1 Investigators.Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med,2007,356:1620-1630.
[36]Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, for the RADIANCE 2 Investigators.Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study):a randomised, double-blind trial. Lancet,2007,370:153-160.
[37]Rano TA, Sieber-McMaster E, Pelton PD, Yang M, Demarest KT, Kuo GH.Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4tetrahydroquinoline platform. Bioorg Med Chem Lett,2009,19:2456-2460.
[38]Kuo GH, Rano T, Pelton P, Demarest KT, Gibbs AC, Murray WV, Damiano BP, Connelly MA. Design, synthesis, and biological evaluation of (2R, alphaS)-3,4-dihydro-2-[3-(1,1,2,2tetrafluoroethoxy)phenyl]-5-[3-(trifluorometho xy)-phenyl]alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. J Med Chem,2009, 52:1768-1772.
[39]Bruce C, Beamer LJ, Tall AR.The implications of the structure of the bactericidal/permeability increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol,1998,8:426-434.
[40]Kawano K, Qin SC, Lin M, Tall AR, Jiang XC.Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo. J Biol Chem,2000,275:29477-29481.
[41]Tall AR.Plasma cholesteryl ester transfer protein. J Lipid Res,1993,34:1255-1274.
[42]Drayna D, Jarnagin AS, McLean J, Henzel W, Koehr W, Fielding C, Lawn R.Cloning and sequencing of human cholestryl ester transfer protein cDNA. Nature,1987,327(61234):632-634.
[43]Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR.Organization of the human cholesteryl ester transfer protein gene. Biochemistry,1990,29(6):1372-1376.
[44]Dullaart RPF, Sluiter WJ.Common variation in the CETP gene and the implications for cardiovascular disease and its treatment:an updated analysis. Pharmacogenomics,2008,9(6):747-763.
[45]Qiu X, Mistry A, Ammirati MJ, Chrunyk BA, Clark RW, Cong Y, Culp JS, Danley DE, Freeman TB, Geoghegan KF, Griffor MC, Hawrylik SJ, Hayward CM, Hensley P, Hoth LR, Karam GA, Lira ME, Lloyd DB, McGrath KM, Stutzman-Engwall KJ, Subashi AK, Subashi TA, Thompson JF, Wang IK, Zhao H, Seddon AP.Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol,2007,14:106-113.
[46]Jiang XC, Bruce C, Cocke T, Wang S, Boguski M, Tall AR.Point mutagenesis of positively charged amino acids of cholesteryl ester transfer protein:conserved residues within the lipid transfer/lipopolysaccharide binding protein gene family essential for function. Biochemistry,1995,34(21):7258-7263.
[47]Pape ME, Ulrich RG, Rea TJ, Marotti KR, Melchior GW.Evidence that the nonparenchymal cells of the liver are the principal source of cholesteryl ester transfer protein in primates. J Biol Chem,1991,266(20):12829-12831.
[48]Martin LJ, Connelly PW, Nancoo D, Wood N, Zhang ZJ, Maguire G, Quinet E, Tall AR, Marcel YL, McPherson R.Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in man:relationship to apoprotein E genotype. J Lipid Res,1993,34:437-446.
[49]Radeau T, Lau P, Robb M, McDonnell M, Ailhaud G, McPherson R.Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J Lipid Res,1995,36:2552-2561.
[50]Tall AR (1993) Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274
[51]Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR.Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol,2003,23:160-167.
[52]Benoist F, Lau P, McDonnell M, Doelle H, Milne R, McPherson R.Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue. J Biol Chem,1997,272(38): 23572-23577.
[53]Gue'rin M, Dolphin PJ, Chapman MJ.Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb,1994,14:679-685.
[54]Bruce C, Davidson WS, Kussie P, Lund-Katz S, Phillips MC, Ghosh R, Tall AR.Molecular determinants of plasma cholesteryl ester transfer protein binding to high density lipoprotein.J Biol Chem,1995,270(19):11532-11542.
[55]Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis,1984,4:225-231.
[56]Hamilton JA, Deckelbaum RJ. Crystal structure of CETP:new hopes for raising HDL to decrease risk of cardiovascular disease? Nat Struct Mol Biol.2007,14: 95-97.
[57]Kontush A, Capman MJ.Functionally defective HDL:a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev,2006.3:342-374.
[58]Kontush A, Guerin M, Chapman MJ,Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med,2008,5(6): 329-336.
[59]Glomset JA.The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res,1968,9:155-167.
[60]Ross R, Glomset JA.Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science,1973,180:1332-1339.
[61]Badimon JJ, Badimon L, Fuster V.Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest, 1990,85:1234-1241.
[62]Moreno PR, Sanz J, Fuster V.Promoting mechanisms of vascular health. J Am Coll Cardiol,2009,53(25):2315-2325.
[63]Yancey PG, Bortnick AE, Kellner-Weibel G, de-la Llera-Moya M, Phillips MC, Rothblat GH.Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol,2003,23:712-719.
[64]Takahashi Y, Smith JD.Cholesterol efflux to apolipoprotein Al involves endocytosis and re-secretion in a calcium-dependent pathway. Proc Natl Acad Sci USA,1999,96:11358-11363.
[65]Williams DL, Connelly MA, Temel RE, Swarnakar S, Phillips MC, de la Llera-Moya M, Rothblat GH.Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol,1999,10:329-339.
[66]Brewer HB Jr.High-density lipoproteins:a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol, 2004,24(3):387-391.
[67]Schwartz CC, Vlahcevic ZR. Berman M, Meadows JG, Nisman RM, Swell L.Central role of high density lipoprotein in plasma free cholesterol metabolism. J Clin Invest,1982,70(1):105-116.
[68]Schwartz CC, Vlahcevic ZR, Halloran LG, Swell L.An in vivo evaluation in man of the transfer of esterified cholesterol between lipoproteins and into the liver and bile. Biochim Biophys Acta,1981,663(1):143-162.
[69]Schwartz CC, Berman M, Vlahcevic ZR, Halloran LG, Gregory DH, Swell L.Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites. J Clin Invest,1978,61(2):408-423.
[70]Lewis GF, Rader DJ.New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res,2005,96:1221-1232.
[71]Petoumenos V, Nickenig G, Werner N.High density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med,2008,13(11): 4623-4635.
[72]Barter PJ, Baker PW, Rye KA.Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol, 2002,13:285-288.
[73]Kontush A, Chapman MJ.Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med,2006,3:342-374.
[74]Atzmon G, Rincon M, Rabizadeh P, Barzilai N.Biological evidence for inheritance of exceptional longevity. Mech Ageing Dev,2005,126:341-345.
[75]Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL,Lipton R, Cheng S, Shuldiner AR.Unique lipoprotein phenotype and genotype associated with exceptional longevity. J Am Med Assoc,2003,290:2030-2040.
[76]Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR.A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res,2004,45:948-953.
[77]Franceschini G, Sirtori M, Gianfranceschi G Sirtori CR.Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality. Metab Clin Exp,1981,30(5):502-509.
[78]Franceschini G, Calabresi L.Normal vascular function despite low levelsof high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I-Milano mutant. Circulation,2007,116:2165-2172.
[79]Franceschini G, Calabresi L, Chiesa G, Parolini C, Sirtori CR,Canavesi M, Bernini F.Increased cholesterol efflux potential of sera from apoAI Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol,1999,19:1257-1262.
[80]Calabresi L, Canavesi M, Bernini F, Franceschini GCell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry,1999,38:16307-16314
[81]Bielicki JK, Oda MN.Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry,2010,41:2089-2096.
[82]Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK.Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol,2006,48:1459-1468.
[83]Parolini C, Chiesa G, Gong E, Caligari S, Cortese MM, Koga T, Forte TM, Rubin EM.Apolipoprotein A-I and the molecular variant apoAIMilano: evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis,2005,183:222-229.
[84]Lebherz C, Sanmiguel J, Wilson J, Rader D.Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol,2007,6:15.
[85]Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ,Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R.Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial. JAMA,2003,290:2292-2300.
[86]Nicholls SJ, Tuzcu EM, Crowe T, Sipahi I, Schoenhagen P,Kapadia S, Hazen SL, Wun CC, Norton M, Ntanios F, Nissen SE.Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol,2006,47:1967-1975.
[87]Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M, Rothblat GH, Phillips MC, Rader DJ.Macrophage reverse cholesterol transport in mice expressing apoA-1 Milano. Arterioscler Thromb Vasc Biol.2009,29: 1496-1501.
[88]Inazu A, Quinet EM, Wang S, Brown ML, Stevenson S, Barr ML, Moulin P, Tall AR.Alternative splicing of the mRNA encoding human cholesteryl ester transfer protein. Biochemistry,1992,31:2352-2358.
[89]Quinet E, Yang TP, Marinos C, Tall A.Inhibition of the cellular secretion of cholesteryl ester transfer protein by a variant protein formed by alternative splicing of mRNA. J Biol Chem,1993,268:16891-16894.
[90]Yamashita S, Hirano KI, Sakai N, Matsuzawa Y.Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta,2010,1529:257-275.
[91]Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y.Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omaguri area of Japan. Arterioscler Thromb Vasc Biol,1997,17:1053-1059.
[92]Nagano M, Yamashita S, Hirano K, Takano M, Maruyama T, Ishihara M, Sagehashi Y, Kujiraoka T, Tanaka K, Hattori H, Sakai N, Nakajima N, Egashira T, Matsuzawa Y.Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb,2004,11(3):110-121.
[93]Rhyne J, Ryan MJ, White C, Chimonas T, Miller M.The two novel CETP mutations GIn87X and GIn165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med,2006,84:647-650.
[94]Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Tall AR.Increased coronary heart disease in Japanese American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest,1996, 97:2917-2923.
[95]MacLean PS, Vadlamudi S, Mac Donald KG, Pories WJ, Barakat HA. Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus. J Clin Endocrinol Metabol,2005,90:2250-2258.
[96]Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ.Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol,2005,16:139-145.
[97]Boekholdt SM, Thomson JF.Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res,2005,44:1080-1093.
[98]Thompson A, DiAngelantonio E, Sarwar N, Erqou S, Salcheen D, Dillaart RPF, Keavney B, Ye Z, Danesh J.Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA,2008,299(23):2777-2788.
[99]Sirtori CR, Mombelli G.Viability of developing CETP inhibitors. Cardiovasc Ther,2008,26:135-146.
[100]Agellon LB, Walsh A, Ayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem,1991,266:10796-10801.
[101]Jiang XC, Masucci-Magoulas L, Mar J, Lin M, Walsh A, reslow JL, Tall A.Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein: mechanism to explain accumulation of lipoprotein B particles. J Biol Chem,1993,268:27406-27412.
[102]Haraki T, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H.Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis,1997,132:229-236.
[103]Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJG, Jukema JW, Luben R, Bingham SA, Day NE, Kastelein JJP, Khaw KT.Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women:the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study. Circulation,2004,110:1418-1423.
[104]De Grooth GJ, Smilde TJ, van Wissen S, Klerkx AHEM, Zwinderman AH, Fruchart JC, Kastelein JJP, Stalenhoef AFH, Kuivenhoven JA.The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis,2004,173:261-267.
[105]Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U.The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis,2010,169:113-120.
[106]Thomas LJ, Hammond RA, Forsberg EM, Geoghegan-Barek KM, Karalius BH, Marsh HC Jr, Ritterhaus CW.Coadministration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum Vaccin,2011,5(2):79-84.
[107]Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ.Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res,2006,47:537-552.
[108]Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED,Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ.Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein:an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol,2004,24:490-497.
[109]Davidson MH, McKenney JM, Shear CL, Revkin JH.Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol,2006,48:1774-1781.
[110]Mc Kenney JM, Davidson MH, Shear CL, Revkin JH.Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol,2006,48:1782-1790.
[111]Hu X, Dietz JD, Xia C, Loging Knight DR, WT Smith AH, Yuan H, Perry DA, Keiser J.Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology,2009,50(5):2211-2219.
[112]Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M 3rd, West SH, White V, Woltmann RF.Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol,2008,154:1465-1473.
[113]Schmeck C, Gielen-Haertwig H, Vakalopoulos A, Bischoff H, Li V, Wirtz Q Weber O.Novel tetrahydrochinoline derived CETP inhibitors. Bioorg Med Chem Lett,2010,20(5):1740-1743.
[114]Boettcher M, Heinig R, Schafer A, Wensing GSafety, tolerability, pharmacodynamics and pharmacokinetics of BAY 60-5521—a new CETP inhibitor. 0th World Conf Clin Pharmacol Ther (July 27-August 1, Quebec), 2008, Abstract T2H023.
[115]Maeda K,et al.S-(2-(acylamino)phenyl)2,2- dimethylpropanethioates as CETP inhibitors. Bioorg Med Chem Lett,2004,14(10):2589-2591.
[116]Shinkai H, Maeda K, Yamasaki T, Okamoto H, Uchida I.Bis(2-(Acylamino) phenyl) disulfides,2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J Med Chem,2000,43(19):3566-3572.
[117]De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J,Zwinderman AH, Posma JL, van Tol A, Kastelein JJ.Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans:a randomized phase Ⅱ dose-response study. Circulation,2010,105(18):2159-2165.
[118]Stein EA, Stroes ESG, Steiner G, Buckley BM DPhild, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJP.Safety and Tolerability of dalcetrapib. Am J Cardiol,2009,104:82-91.
[119]Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J,Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA.Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet 2007,370(9603):1907-1914.
[120]Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM,Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC.Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J,2009,157(2):352-360.
[121]Cunningham D, Lin W, Hoth LR, Danley DE, Ruggeri RB, Geoghegan KF, Chrunyk BA, Boyd JG.Biophysical and biochemical approach to locating an inhibitor binding site on cholestreyl ester transfer protein. Bioconjug Chem,2008,19:1604-1613.
[122]Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H.A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature,2009,406:203-207.
[123]Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ.Description of the torcetrabip series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res,2010,47:537-552.
[124]Cannon CP, Dansky HM, Davidson M, Gotto AM Jr., Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P, DEFINE investigators Design of the DEFINE trial. Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J,2009,158(4):513-519.